At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)biological
Likely dose
Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis) 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Bridging Study to Assess the Safety of the Vaccine Adacel® in a Clinical Trial
In Brief
A Phase 3 clinical trial evaluating Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis) for Diphtheria and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The objective of this study is to describe the safety of Adacel® vaccination in adults subjects in Vietnam. This study is conducted in accordance with Vietnamese regulation in support to Adacel® registration. Primary objective: To monitor the adverse effects of the vaccine ADACEL® from day 0 to day 30 after immunization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiphtheria, Tetanus, Pertussis
CountriesVietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedDec 2009
Primary CompletionFeb 2010
Study CompletionApr 2010
TodayJul 2026
First PostedDec 25, 2009
Enrollment StartDec 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.5 years ago
Interventions
Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)biological
0.5 mL, Intramuscular